CA2647360A1 - Methods and compositions for deterring abuse of orally administered pharmaceutical products - Google Patents

Methods and compositions for deterring abuse of orally administered pharmaceutical products Download PDF

Info

Publication number
CA2647360A1
CA2647360A1 CA002647360A CA2647360A CA2647360A1 CA 2647360 A1 CA2647360 A1 CA 2647360A1 CA 002647360 A CA002647360 A CA 002647360A CA 2647360 A CA2647360 A CA 2647360A CA 2647360 A1 CA2647360 A1 CA 2647360A1
Authority
CA
Canada
Prior art keywords
alkyl
esters
irritant
composition
ethoxylates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002647360A
Other languages
French (fr)
Other versions
CA2647360C (en
Inventor
James F. Emigh
Andrew D. Reddick
Ron J. Spivey
Ronald L. Leech, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acura Pharmaceuticals Inc
Original Assignee
Acura Pharmaceuticals, Inc.
James F. Emigh
Andrew D. Reddick
Ron J. Spivey
Ronald L. Leech, Jr.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acura Pharmaceuticals, Inc., James F. Emigh, Andrew D. Reddick, Ron J. Spivey, Ronald L. Leech, Jr. filed Critical Acura Pharmaceuticals, Inc.
Publication of CA2647360A1 publication Critical patent/CA2647360A1/en
Application granted granted Critical
Publication of CA2647360C publication Critical patent/CA2647360C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

This invention relates to an abuse deterrent formulation of an oral dosage form of a therapeutically effective amount of any active drug substance that can be subject to abuse combined with a gel forming polymer, a nasal mucosal irritating surfactant and a flushing agent. Such a dosage form is intended to deter abuse of the active drug substance via injection, nasal inhalation or consumption of quantities of the dosage unit exceeding the usual therapeutically effective dose.

Claims (20)

1. A therapeutic pharmaceutical composition comprising (a) an opioid analgesic;

(b) a gel forming polymer;

(c) a nasal tissue irritant having a slight amount or greater degree of irritancy; and (d) a flushing agent in sufficient amount to cause flushing if greater than a prescribed amount of the analgesic of the therapeutic composition is ingested.
2. The composition of claim 1, wherein the nasal tissue irritant comprises one or more of a foaming agent, anti-foaming agent, dispersant, emulsifier, solubilizer, emollient, gel enhancer, detergent, chelating agent and wetting agent.
3. The composition of claim 1, wherein the nasal tissue irritant comprises one or more of ethylene oxide/propylene oxide copolymers, polyoxyethylene/polyoxypropylene copolymers, polyoxyethylene/polypropylene copolymers, polyoxyethylene/polybutylene copolymers, perfluoropolyether ammonium carboxylate, sulfates, sulfonates, phosphates, ammonium compounds, amines, amides, silicones, silicates, sarcosines, alcohols, ethers, ethoxylates, esters, organic acids, plant oils, sulfosuccinates, taurate salts, edtas, alkyl iminodipropionates, alkyl imidazoline derivatives, alkyl pyridinium salts, lanolin derivatives, protein derivatives, alkyl polyglycosides, alkyl oligosaccharides, cyclodextrins, lecithins, betaines and sultaines.
4. The composition of claim 1, wherein the nasal tissue irritant comprises one or more of alkyl sulfates, lauryl sulfates, alkyl sulfate salts, alkyl ether sulfates, alkaryl ether sulfates, sulfated fats, sulfated monoglycerides, sulfated alkanolamides, olefin sulfonates, alkylaryl sulfonates, polyether sulfonates, naphthalene sulfonates, phosphate esters, alkyl phosphates, alkyl phosphate salts, alkyl ether phosphates, alkyl ammonium salts, alkyl trimethylammonium salts, quaternary ammonium chlorides, alkyl amines, amine oxides, ethoxylated amines, alkyl aminopropionates, alkanolamides, diethanolamides, monoisopropanolamides, monoethanolamides, amido amines, dimethicones, simethicone, silicates, lauryl sarcosines, cocoyl sarcosines, ethoxylated alcohols, propoxylated alcohols, alkyl alcohols, glycols, polyethylene glycols, acetylenic alcohol, glycol ethers, ethoxylated glycerine, polyoxyethylene alkyl ethers, lanolin ethoxylates, octyl phenol ethoxylates, nonyl phenol ethoxylates, oleic acid ethoxylates, cocoamine ethoxylates, tallow amine ethoxylates, stearic acid ethoxylates, fatty acid ethoxylates, ethoxylated sorbitan esters, methyl esters and blends, sobitan esters, sucrose esters, fatty acid esters, polyethylene glycol esters, alcohol esters, glycerol esters, glycol esters, butyl and isopropyl esters, sulfosuccinate esters, sulfuric acid esters, alkyl carboxylates, alkyl ether carboxylates, lactylates, glutamates, sarcosinates, carboxylic acids and fatty acids.
5. The compostion of claim 1, wherein the nasal tissue irritant is a slight irritant.
6. The composition of claim 1, wherein the nasal tissue irritant is a moderate irritant.
7. The composition of claim 1, wherein the nasal tissue irritant is a severe irritant.
8. The composition of claim 1, wherein the nasal tissue irritant is a toxic irritant.
9. The composition of claim 2, wherein at least a portion of the irritant is sequestered.
10. The composition of claim 3, wherein at least a portion of the irritant is sequestered.
11. The composition of claim 4, wherein at least a portion of the irritant is sequestered.
12. A therapeutic pharmaceutical composition comprising (a) an analgesic;

(b) a gel forming polymer;

(c) a mucosal tissue irritant comprising one or more of a foaming agent, anti-foaming agent, dispersant, emulsifier, solubilizer, emollient, gel enhancer, detergent, chelating agent and wetting agent; and (d) a flushing agent in sufficient amount to cause flushing if greater than a prescribed amount of the analgesic of the therapeutic composition is ingested.
13. A therapeutic pharmaceutical composition comprising (a) an opioid analgesic;

(b) means for blocking one or more of the sphenoid, maxillary, ethmoid and frontal sinuses;
(c) a nasal tissue irritant; and (d) a flushing agent in sufficient amount to cause flushing if greater than a prescribed amount of the analgesic of the therapeutic composition is ingested.
14. The composition of claim 13, wherein the nasal tissue irritant comprises one or more of a foaming agent, anti-foaming agent, dispersant, emulsifier, solubilizer, emollient, gel enhancer, detergent, chelating agent and wetting agent.
15. The composition of claim 13, wherein the nasal tissue irritant comprises one or more of ethylene oxide/propylene oxide copolymers, polyoxyethylene/polyoxypropylene copolymers, polyoxyethylene/polypropylene copolymers, polyoxyethylene/polybutylene copolymers, perfluoropolyether ammonium carboxylate, sulfates, sulfonates, phosphates, ammonium compounds, amines, amides, silicones, silicates, sarcosines, alcohols, ethers, ethoxylates, esters, organic acids, plant oils, sulfosuccinates, taurate salts, edtas, alkyl iminodipropionates, alkyl imidazoline derivatives, alkyl pyridinium salts, lanolin derivatives, protein derivatives, alkyl polyglycosides, alkyl oligosaccharides, cyclodextrins, lecithins, betaines and sultaines.
16. The composition of claim 13, wherein the nasal tissue irritant comprises one or more of alkyl sulfates, lauryl sulfates, alkyl sulfate salts, alkyl ether sulfates, alkaryl ether sulfates, sulfated fats, sulfated monoglycerides, sulfated alkanolamides, olefin sulfonates, alkylaryl sulfonates, polyether sulfonates, naphthalene sulfonates, phosphate esters, alkyl phosphates, alkyl phosphate salts, alkyl ether phosphates, alkyl ammonium salts, alkyl trimethylammonium salts, quaternary ammonium chlorides, alkyl amines, amine oxides, ethoxylated amines, alkyl aminopropionates, alkanolamides, diethanolamides, monoisopropanolamides, monoethanolamides, amido amines, dimethicones, simethicone, silicates, lauryl sarcosines, cocoyl sarcosines, ethoxylated alcohols, propoxylated alcohols, alkyl alcohols, glycols, polyethylene glycols, acetylenic alcohol, glycol ethers, ethoxylated glycerine, polyoxyethylene alkyl ethers, lanolin ethoxylates, octyl phenol ethoxylates, nonyl phenol ethoxylates, oleic acid ethoxylates, cocoamine ethoxylates, tallow amine ethoxylates, stearic acid ethoxylates, fatty acid ethoxylates, ethoxylated sorbitan esters, methyl esters and blends, sobitan esters, sucrose esters, fatty acid esters, polyethylene glycol esters, alcohol esters, glycerol esters, glycol esters, butyl and isopropyl esters, sulfosuccinate esters, sulfuric acid esters, alkyl carboxylates, alkyl ether carboxylates, lactylates, glutamates, sarcosinates, carboxylic acids and fatty acids.
17. The compostion of claim 13, wherein the nasal tissue irritant is a slight irritant.
18. The composition of claim 13, wherein the nasal tissue irritant is a moderate irritant.
19. The composition of claim 13, wherein the nasal tissue irritant is a severe irritant.
20. The composition of claim 13, wherein at least a portion of the irritant is sequestered.
CA2647360A 2006-03-15 2007-03-14 Methods and compositions for deterring abuse of orally administered pharmaceutical products Expired - Fee Related CA2647360C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78244806P 2006-03-15 2006-03-15
US60/782,448 2006-03-15
PCT/US2007/006519 WO2007106550A2 (en) 2006-03-15 2007-03-14 Methods and compositions for deterring abuse of orally administered pharmaceutical products

Publications (2)

Publication Number Publication Date
CA2647360A1 true CA2647360A1 (en) 2007-09-20
CA2647360C CA2647360C (en) 2012-05-15

Family

ID=38510088

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2647360A Expired - Fee Related CA2647360C (en) 2006-03-15 2007-03-14 Methods and compositions for deterring abuse of orally administered pharmaceutical products

Country Status (5)

Country Link
EP (1) EP1993519A4 (en)
AU (1) AU2007225101A1 (en)
CA (1) CA2647360C (en)
IL (1) IL193766A0 (en)
WO (1) WO2007106550A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010069050A1 (en) * 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
US8691270B2 (en) 2007-12-17 2014-04-08 Paladin Labs Inc. Misuse preventative, controlled release formulation

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
ATE495732T1 (en) 2003-03-26 2011-02-15 Egalet As CONTROLLED RELEASE MORPHINE SYSTEM
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
AU2015200313B2 (en) * 2007-12-17 2016-12-01 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10250084A1 (en) * 2002-10-25 2004-05-06 Grünenthal GmbH Dosage form protected against abuse
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691270B2 (en) 2007-12-17 2014-04-08 Paladin Labs Inc. Misuse preventative, controlled release formulation
US8920834B2 (en) 2007-12-17 2014-12-30 Paladin Labs Inc. Misuse preventative, controlled release formulation
US8920833B2 (en) 2007-12-17 2014-12-30 Paladin Labs Inc. Misuse preventative, controlled release formulation
WO2010069050A1 (en) * 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
US8927013B2 (en) 2008-12-16 2015-01-06 Paladin Labs Inc. Misuse preventative, controlled release formulation
US8927014B2 (en) 2008-12-16 2015-01-06 Paladin Labs Inc. Misuse preventative, controlled release formulation

Also Published As

Publication number Publication date
EP1993519A4 (en) 2011-12-21
IL193766A0 (en) 2011-08-01
WO2007106550A2 (en) 2007-09-20
CA2647360C (en) 2012-05-15
WO2007106550A3 (en) 2008-06-12
EP1993519A2 (en) 2008-11-26
AU2007225101A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
CA2647360A1 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
US8569373B2 (en) Compositions comprising A C2-C14 carboxylic acid and a surfactant for treating hoof diseases
EP2934480B1 (en) Germicidal compositions comprising carboxylic acid mixture and use as topical disinfectants
AU2002337677B2 (en) Wipe formulation
US11166912B2 (en) Orally administrable composition
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
Puratchikody et al. Buccal drug delivery: past, present and future-a review
US20200276315A1 (en) Povidone-iodine topical composition
JP2010524976A (en) Antibacterial composition, product and method of use
AU2002337677A1 (en) Wipe formulation
RS20060479A (en) Novel compositions for topical delivery
JP2014530242A5 (en)
JP2014503565A5 (en)
EP2470172A1 (en) Pharmaceutical formulations and methods of use
DK1409022T3 (en) Pharmaceutical mousse composition comprising salicylic acid
JP2009502985A5 (en)
KR20110091862A (en) Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
JP2022031733A (en) Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions
CA2931858C (en) Long-acting ketoprofen compositions
ES2388236T3 (en) Metronidazole solubilization procedure with the help of niacinamide and two glycols, solution thus obtained
US20120301409A1 (en) Homeopathic composition and method for the treatment of skin irritations and other skin diseases
US20080311053A1 (en) Fluorinated phosphate ester surfactant and fluorinated alcohol compositions
CA2499900A1 (en) Dri nasal sprays
JP2007246459A5 (en)
US20220226240A1 (en) Orally administrable composition

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190314